Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

4(66.7%)

Phase 2

1(16.7%)

Phase 1

1(16.7%)

6Total

N/A(4)

Phase 2(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT00471302Completed

Normal Immunological Parameters Among Healthy Volunteers in Kambila, Mali

Role: collaborator

NCT04912284Completed

Africa COVID-19 Vaccine Hesitancy

Role: collaborator

NCT01015950Not ApplicableCompleted

Management of Children With Moderate Acute Malnutrition in Mali

Role: collaborator

NCT02646410Not ApplicableUnknown

Optimization of Seasonal Malaria Chemoprevention (SMC) Delivery

Role: lead

NCT02894294Completed

Evaluation of Seasonal Malaria Chemoprevention in Kita

Role: lead

NCT01341704Phase 2Completed

Proof-of-Concept Study of MSP3-LSP Vaccine to Protect Against Malaria in Africa

Role: collaborator

NCT01645254Phase 1Unknown

Phase 1b Malaria Clinical Trial Using Argemone Mexicana in Healthy Adults in Mali

Role: lead

NCT00766662Not ApplicableCompleted

Intermittent Preventive Treatment in Infant in Mali

Role: lead

NCT00623155Not ApplicableCompleted

Seasonal Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine in Children in Mali

Role: lead

All 9 trials loaded